Sold as Dymelor. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 13, 2026, FDA lists 6 applications for Acetohexamide (sold as Dymelor), first approved Dec 23, 1964, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 23, 1964 | DymelorNDA 13378 · New molecular entity | Lilly | 17 | Discontinued |
| Feb 9, 1987 | AcetohexamideANDA 70870 | Ani Pharms | 18 | Discontinued |
| Nov 25, 1987 | AcetohexamideANDA 71893 | Watson Labs Teva | 7 | Discontinued |
| Nov 25, 1987 | AcetohexamideANDA 71894 | Watson Labs Teva | 6 | Discontinued |
| — | AcetohexamideANDA 70753 | Usl Pharma | 0 | Discontinued |
| — | AcetohexamideANDA 70754 | Usl Pharma | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Lilly